Scancell Holdings PLC - Oxford, England-based developer of immunotherapies for treatment of cancer and infectious disease - Plans clinical trial in South Africa and the UK for its novel bivalent Covid-19 vaccine candidates, after pre-clinical data showed positive immune responses. Says its leading vaccine candidates, SCOV1 and SCOV2, could provide higher protection against new variants of Covid-19. Notes it can continue to target emerging variants using its ImmunoBody DNA vaccine platform.
Pending regulatory approval, the trial's first phase will begin at the University of Cape Town Lung Institute in South Africa. Says the first phase will test its vaccines on healthy, unvaccinated young adults who have never had Covid-19. Such volunteers were unavailable in the UK, due to its speedy vaccine rollout. The second, UK-based, phase will assess the effectiveness of the vaccines on healthy adults who have already been given two doses of an approved vaccine.
The trial is the next stage in Scancell's Covidity programme, developed alongside Nottingham Trent University the University of Nottingham's recently established Centre for Research on Global Virus Infections, and Biodiscovery Institute.
Current stock price: 22.00 pence, up 3.5% on Tuesday
Year-to-date change: up 57%
By Scarlett Butler; scarlettbutler@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
Scancell Holdings (SCLP)